Logo image of CLGN

COLLPLANT BIOTECHNOLOGIES LT (CLGN) Stock Fundamental Analysis

USA - NASDAQ:CLGN - IL0004960188 - Common Stock

2.46 USD
-0.07 (-2.77%)
Last: 10/2/2025, 8:00:01 PM
2.44 USD
-0.02 (-0.81%)
After Hours: 10/2/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, CLGN scores 3 out of 10 in our fundamental rating. CLGN was compared to 536 industry peers in the Biotechnology industry. CLGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CLGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLGN has reported negative net income.
In the past year CLGN has reported a negative cash flow from operations.
In the past 5 years CLGN reported 4 times negative net income.
CLGN had negative operating cash flow in 4 of the past 5 years.
CLGN Yearly Net Income VS EBIT VS OCF VS FCFCLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -80.58%, CLGN is not doing good in the industry: 68.28% of the companies in the same industry are doing better.
With a Return On Equity value of -111.85%, CLGN perfoms like the industry average, outperforming 42.72% of the companies in the same industry.
Industry RankSector Rank
ROA -80.58%
ROE -111.85%
ROIC N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
CLGN Yearly ROA, ROE, ROICCLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

CLGN has a better Gross Margin (48.71%) than 75.19% of its industry peers.
CLGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLGN Yearly Profit, Operating, Gross MarginsCLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLGN remains at a similar level compared to 1 year ago.
CLGN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLGN Yearly Shares OutstandingCLGN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CLGN Yearly Total Debt VS Total AssetsCLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -7.43, we must say that CLGN is in the distress zone and has some risk of bankruptcy.
CLGN has a worse Altman-Z score (-7.43) than 66.79% of its industry peers.
CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.43
ROIC/WACCN/A
WACC8.81%
CLGN Yearly LT Debt VS Equity VS FCFCLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

CLGN has a Current Ratio of 4.48. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.48, CLGN perfoms like the industry average, outperforming 49.63% of the companies in the same industry.
CLGN has a Quick Ratio of 4.23. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CLGN (4.23) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.48
Quick Ratio 4.23
CLGN Yearly Current Assets VS Current LiabilitesCLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.91% over the past year.
Looking at the last year, CLGN shows a very negative growth in Revenue. The Revenue has decreased by -95.30% in the last year.
CLGN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.99% yearly.
EPS 1Y (TTM)16.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.32%
Revenue 1Y (TTM)-95.3%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%-28.11%

3.2 Future

Based on estimates for the next years, CLGN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.70% on average per year.
Based on estimates for the next years, CLGN will show a very strong growth in Revenue. The Revenue will grow by 103.99% on average per year.
EPS Next Y77.99%
EPS Next 2Y40.31%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue Next Year428.63%
Revenue Next 2Y211.49%
Revenue Next 3Y103.99%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLGN Yearly Revenue VS EstimatesCLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
CLGN Yearly EPS VS EstimatesCLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLGN. In the last year negative earnings were reported.
Also next year CLGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLGN Price Earnings VS Forward Price EarningsCLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLGN Per share dataCLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as CLGN's earnings are expected to grow with 25.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.31%
EPS Next 3Y25.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COLLPLANT BIOTECHNOLOGIES LT

NASDAQ:CLGN (10/2/2025, 8:00:01 PM)

After market: 2.44 -0.02 (-0.81%)

2.46

-0.07 (-2.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20 2025-08-20/bmo
Earnings (Next)11-03 2025-11-03
Inst Owners17.04%
Inst Owner Change15.68%
Ins Owners29.91%
Ins Owner ChangeN/A
Market Cap31.29M
Analysts82.5
Price Target11.73 (376.83%)
Short Float %0.41%
Short Ratio1.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-119.92%
Min EPS beat(2)-218.63%
Max EPS beat(2)-21.21%
EPS beat(4)0
Avg EPS beat(4)-76.23%
Min EPS beat(4)-218.63%
Max EPS beat(4)-21.21%
EPS beat(8)1
Avg EPS beat(8)296.42%
EPS beat(12)1
Avg EPS beat(12)161.42%
EPS beat(16)1
Avg EPS beat(16)99.24%
Revenue beat(2)0
Avg Revenue beat(2)-43.31%
Min Revenue beat(2)-62.78%
Max Revenue beat(2)-23.83%
Revenue beat(4)0
Avg Revenue beat(4)-56.16%
Min Revenue beat(4)-99.06%
Max Revenue beat(4)-23.83%
Revenue beat(8)1
Avg Revenue beat(8)-51.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.17%
PT rev (3m)-17.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-366.67%
EPS NY rev (1m)-1.61%
EPS NY rev (3m)-186.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.82%
Revenue NY rev (1m)-18.2%
Revenue NY rev (3m)-24.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.66
P/FCF N/A
P/OCF N/A
P/B 2.52
P/tB 2.55
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.19
BVpS0.97
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -80.58%
ROE -111.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.71%
FCFM N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.92%
Cap/Sales 16.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.48
Quick Ratio 4.23
Altman-Z -7.43
F-Score2
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)85.11%
Cap/Depr(5y)108.12%
Cap/Sales(3y)180.83%
Cap/Sales(5y)112.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.32%
EPS Next Y77.99%
EPS Next 2Y40.31%
EPS Next 3Y25.7%
EPS Next 5YN/A
Revenue 1Y (TTM)-95.3%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%-28.11%
Revenue Next Year428.63%
Revenue Next 2Y211.49%
Revenue Next 3Y103.99%
Revenue Next 5YN/A
EBIT growth 1Y-75.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.87%
OCF growth 3YN/A
OCF growth 5YN/A